SMARCA4 and non-small cell lung carcinoma: However, as the outlier in this critical review focusing on KRAS G12D, the SMARCA4/KRAS G12C co-mutation OS analysis did not result in a significant difference as compared to SMARCA4 WT/KRAS-mutated NSCLC patients (6.1 vs. 17.3 months; p = 0.42) [34].